Milk fermented by Lactobacillus casei CRL431 modifies cytokine profiles associated to different stages of breast cancer development in mice
äºBeneficial MicrobesSearch for other papers by V.E. Méndez Utz in
Current site
Google Scholar
Cátedra de InmunologÃa. Facultad de BioquÃmica, QuÃmica y Farmacia. Universidad Nacional de Tucumán, San Miguel de Tucumán, Tucumán, Argentina.
Search for other papers by G. Perdigón in
Current site
Google Scholar
Search for other papers by A. de Moreno de LeBlanc in
Current site
Google Scholar
Breast cancer is one of the leading causes of death worldwide. It is recognised that immune system influences its promotion, progression, and metastasis, as well as their responsiveness to therapies. Previously, it was reported that milk fermented by Lactobacillus casei CRL431 decreased tumour growth and metastasis in a mouse breast cancer model, through the modulation of the host immune response. The aim of the present work was to analyse the systemic immune response induced by the administration of probiotic fermented milk (PFM) at different stages of cancer development, evaluating cytokines produced by splenocytes stimulated in vitro with 4T1 tumour cells, or its conditioned medium (CM). Groups of healthy mice and mice bearing 4T1 tumour or suffering metastasis after tumour surgery were studied. Results showed that at the early stages, PFM maintained pro-inflammatory response associated to the delay or the inhibition of tumour growth. PFM administration to mice bearing tumour maintained an important inflammatory response; however, in contrast to the milk group, this response was regulated to avoid exacerbation of inflammation. In the metastasis model, the benefits of PFM were associated to avoid the immunosuppression associated to high interleukin-10 levels. In conclusion, as cancer cells induce modifications of the immune response to favour their own growth at each stage of cancer development, PFM administration stimulated different profile of cytokines to respond to these modifications and fight against cancer cells.
Purchase
Buy instant access (PDF download and unlimited online access):
Institutional Login
Log in with Open Athens, Shibboleth, or your institutional credentials
Personal login
Log in with your brill.com account
-
American Cancer Society, 2018. Cancer facts & figures 2017-2018. Available at: http://tinyurl.com/y9dfnpu4.
-
Aragon, F., Carino, S., Perdigon, G. and De Moreno de LeBlanc, A., 2014. The administration of milk fermented by the probiotic Lactobacillus casei CRL 431 exerts an immunomodulatory effect against a breast tumor in a mouse model. Immunobiology 219: 457-464.
'The administration of milk fermented by the probiotic Lactobacillus casei CRL 431 exerts an immunomodulatory effect against a breast tumor in a mouse model ' () 219 Immunobiology : 457 -464.
-
Aragon, F., Carino, S., Perdigon, G. and De Moreno de LeBlanc, A., 2015. Inhibition of growth and metastasis of breast cancer in mice by milk fermented with Lactobacillus casei CRL 431. Journal of Immunotherapy 38: 185-196.
'Inhibition of growth and metastasis of breast cancer in mice by milk fermented with Lactobacillus casei CRL 431 ' () 38 Journal of Immunotherapy : 185 -196.
-
Bertazza, L. and Mocellin, S., 2010. The dual role of tumor necrosis factor (TNF) in cancer biology. Current Medicinal Chemistry 17: 3337-3352.
'The dual role of tumor necrosis factor (TNF) in cancer biology ' () 17 Current Medicinal Chemistry : 3337 -3352.
-
Braumüller, H., Wieder, T., Brenner, E., Aβmann, S., Hahn, M., Alkhaled, M., Schilbach, K., Essmann, F., Kneilling, M., Griessinger, C., Ranta, F., Ullrich, S., Mocikat, R., Braungart, K., Mehra, T., Fehrenbacher, B., Berdel, J., Niessner, H., Meier, F., Van den Broek, M., Häring, H.-U., Handgretinger, R., Quintanilla-Martinez, L., Fend, F., Pesic, M., Bauer, J., Zender, L., Schaller, M., Schulze-Osthoff, K. and Röcken, M., 2013. T-helper-1-cell cytokines drive cancer into senescence. Nature 494: 361.
'T-helper-1-cell cytokines drive cancer into senescence ' () 494 Nature : 361.
-
Chen, D.S. and Mellman, I., 2013. Oncology meets immunology: the cancer-immunity cycle. Immunity 39: 1-10.
'Oncology meets immunology: the cancer-immunity cycle ' () 39 Immunity : 1 -10.
-
Chen, L., Huang, T.G., Meseck, M., Mandeli, J., Fallon, J. and Woo, S.L., 2007. Rejection of metastatic 4T1 breast cancer by attenuation of Treg cells in combination with immune stimulation. Molecular Therapy 15: 2194-2202.
'Rejection of metastatic 4T1 breast cancer by attenuation of Treg cells in combination with immune stimulation ' () 15 Molecular Therapy : 2194 -2202.
-
Dethlefsen, C., Hojfeldt, G. and Hojman, P., 2013. The role of intratumoral and systemic IL-6 in breast cancer. Breast Cancer Research and Treatment 138: 657-664.
'The role of intratumoral and systemic IL-6 in breast cancer ' () 138 Breast Cancer Research and Treatment : 657 -664.
-
Dumeaux, V., Fjukstad, B., Fjosne, H.E., Frantzen, J.O., Holmen, M.M., Rodegerdts, E., Schlichting, E., Borresen-Dale, A.L., Bongo, L.A., Lund, E. and Hallett, M., 2017. Interactions between the tumor and the blood systemic response of breast cancer patients. PLoS Computational Biology 13: e1005680.
'Interactions between the tumor and the blood systemic response of breast cancer patients ' () 13 PLoS Computational Biology : e1005680.
-
Dunn, G.P., Ikeda, H., Bruce, A.T., Koebel, C., Uppaluri, R., Bui, J., Chan, R., Diamond, M., White, J.M., Sheehan, K.C. and Schreiber, R.D., 2005. Interferon-gamma and cancer immunoediting. Immunologic Research 32: 231-245.
'Interferon-gamma and cancer immunoediting ' () 32 Immunologic Research : 231 -245.
-
Faghih, Z., Erfani, N., Haghshenas, M.R., Safaei, A., Talei, A.R. and Ghaderi, A., 2014. Immune profiles of CD4+ lymphocyte subsets in breast cancer tumor draining lymph nodes. Immunology Letters 158: 57-65.
'Immune profiles of CD4+ lymphocyte subsets in breast cancer tumor draining lymph nodes ' () 158 Immunology Letters : 57 -65.
-
Hamidullah Changkija, B. and Konwar, R., 2012. Role of interleukin-10 in breast cancer. Breast Cancer Research and Treatment 133: 11-21.
'Role of interleukin-10 in breast cancer ' () 133 Breast Cancer Research and Treatment : 11 -21.
-
Huang, Y., Ma, C., Zhang, Q., Ye, J., Wang, F., Zhang, Y., Hunborg, P., Varvares, M.A., Hoft, D.F., Hsueh, E.C. and Peng, G., 2015. CD4+ and CD8+ T cells have opposing roles in breast cancer progression and outcome. Oncotarget 6: 17462-17478.
'CD4+ and CD8+ T cells have opposing roles in breast cancer progression and outcome ' () 6 Oncotarget : 17462 -17478.
-
Kano, A., 2015. Tumor cell secretion of soluble factor(s) for specific immunosuppression. Scientific Reports 5: 8913.
'Tumor cell secretion of soluble factor(s) for specific immunosuppression ' () 5 Scientific Reports : 8913.
-
Lippitz, B.E., 2013. Cytokine patterns in patients with cancer: a systematic review. Lancet Oncology 14: e218-228.
'Cytokine patterns in patients with cancer: a systematic review ' () 14 Lancet Oncology : e218 -228.
-
Masuda, J., Takayama, E., Strober, W., Satoh, A., Morimoto, Y., Honjo, Y., Ichinohe, T., Tokuno, S.I., Ishizuka, T., Nakata, T., Mizutani, A., Umemura, N., Kitani, A., Fuss, I.J., Shigehiro, T., Kawaki, H., Mizuno-Kamiya, M., Kondoh, N. and Seno, M., 2017. Tumor growth limited to subcutaneous site vs tumor growth in pulmonary site exhibit differential effects on systemic immunities. Oncology Reports 38: 449-455.
'Tumor growth limited to subcutaneous site vs tumor growth in pulmonary site exhibit differential effects on systemic immunities ' () 38 Oncology Reports : 449 -455.
-
Mendez Utz, V.E., Perdign, G. and De Moreno de LeBlanc, A., 2019. Oral administration of milk fermented by Lactobacillus casei CRL431 was able to decrease metastasis from breast cancer in a murine model by modulating immune response locally in the lungs. Journal of Functional Foods 54: 263-270.
'Oral administration of milk fermented by Lactobacillus casei CRL431 was able to decrease metastasis from breast cancer in a murine model by modulating immune response locally in the lungs ' () 54 Journal of Functional Foods : 263 -270.
-
Merendino, R.A., Arena, A., Capozza, A.B., Chillemi, S. and Mesiti, M., 1996. Serum levels of interleukin-10 in patients affected by breast cancer. Immunology Letters 53: 59-60.
'Serum levels of interleukin-10 in patients affected by breast cancer ' () 53 Immunology Letters : 59 -60.
-
Nakasone, E.S., Hurvitz, S.A. and McCann, K.E., 2018. Harnessing the immune system in the battle against breast cancer. Drugs Context 7: 212520.
'Harnessing the immune system in the battle against breast cancer ' () 7 Drugs Context : 212520.
-
Nocera, N.F., Lee, M.C., De la Cruz, L.M., Rosemblit, C. and Czerniecki, B.J., 2016. Restoring lost anti-HER-2 Th1 immunity in breast cancer: a crucial role for Th1 cytokines in therapy and prevention. Frontiers in Pharmacology 7: 356.
'Restoring lost anti-HER-2 Th1 immunity in breast cancer: a crucial role for Th1 cytokines in therapy and prevention ' () 7 Frontiers in Pharmacology : 356.
-
Pulaski Beth, A. and Ostrand-Rosenberg, S., 2001. Mouse 4T1 breast tumor model. Current Protocols in Immunology 39: 20.22.21-20.22.16.
'Mouse 4T1 breast tumor model ' () 39 Current Protocols in Immunology : 20.22.21 -20.22.16.
-
Schreiber, R.D., Old, L.J. and Smyth, M.J., 2011. Cancer immunoediting: integrating immunityâs roles in cancer suppression and promotion. Science 331: 1565-1570.
'Cancer immunoediting: integrating immunityâs roles in cancer suppression and promotion ' () 331 Science : 1565 -1570.
-
Shankaran, V., Ikeda, H., Bruce, A.T., White, J.M., Swanson, P.E., Old, L.J. and Schreiber, R.D., 2001. IFNgamma and lymphocytes prevent primary tumour development and shape tumour immunogenicity. Nature 410: 1107-1111.
'IFNgamma and lymphocytes prevent primary tumour development and shape tumour immunogenicity ' () 410 Nature : 1107 -1111.
-
Shrihari, T.G., 2017. Dual role of inflammatory mediators in cancer. Ecancermedicalscience 11: 721.
'Dual role of inflammatory mediators in cancer ' () 11 Ecancermedicalscience : 721.
-
Takeda, K., Nakayama, M., Hayakawa, Y., Kojima, Y., Ikeda, H., Imai, N., Ogasawara, K., Okumura, K., Thomas, D.M. and Smyth, M.J., 2017. IFN-gamma is required for cytotoxic T cell-dependent cancer genome immunoediting. Nature Communications 8: 14607.
'IFN-gamma is required for cytotoxic T cell-dependent cancer genome immunoediting ' () 8 Nature Communications : 14607.
-
Vesely, M.D. and Schreiber, R.D., 2013. Cancer immunoediting: antigens, mechanisms, and implications to cancer immunotherapy. Annals of the New York Academy of Sciences 1284: 1-5.
'Cancer immunoediting: antigens, mechanisms, and implications to cancer immunotherapy ' () 1284 Annals of the New York Academy of Sciences : 1 -5.
-
Vinay, D.S., Ryan, E.P., Pawelec, G., Talib, W.H., Stagg, J., Elkord, E., Lichtor, T., Decker, W.K., Whelan, R.L., Kumara, H., Signori, E., Honoki, K., Georgakilas, A.G., Amin, A., Helferich, W.G., Boosani, C.S., Guha, G., Ciriolo, M.R., Chen, S., Mohammed, S.I., Azmi, A.S., Keith, W.N., Bilsland, A., Bhakta, D., Halicka, D., Fujii, H., Aquilano, K., Ashraf, S.S., Nowsheen, S., Yang, X., Choi, B.K. and Kwon, B.S., 2015. Immune evasion in cancer: mechanistic basis and therapeutic strategies. Seminars in Cancer Biology 35: S185-S198.
'Immune evasion in cancer: mechanistic basis and therapeutic strategies ' () 35 Seminars in Cancer Biology : S185 -S198.
-
Welte, T. and Zhang, X.H., 2015. Interleukin-17 could promote breast cancer progression at several stages of the disease. Mediators of Inflammation 2015: 804347.
'Interleukin-17 could promote breast cancer progression at several stages of the disease ' () 2015 Mediators of Inflammation : 804347.
-
Young, S.H., Antonini, J.M., Roberts, J.R., Erdely, A.D. and Zeidler-Erdely, P.C., 2008. Performance evaluation of cytometric bead assays for the measurement of lung cytokines in two rodent models. Journal of Immunological Methods 331: 59-68.
'Performance evaluation of cytometric bead assays for the measurement of lung cytokines in two rodent models ' () 331 Journal of Immunological Methods : 59 -68.
-
Zhou, L., Zhang, X., Li, H., Niu, C., Yu, D., Yang, G., Liang, X., Wen, X., Li, M. and Cui, J., 2018. Validating the pivotal role of the immune system in low-dose radiation-induced tumor inhibition in Lewis lung cancer-bearing mice. Cancer Medicine 7: 1338-1348.
'Validating the pivotal role of the immune system in low-dose radiation-induced tumor inhibition in Lewis lung cancer-bearing mice ' () 7 Cancer Medicine : 1338 -1348.
| å ¨é¨æé´ | è¿å»ä¸å¹´ | è¿å»30天 | |
|---|---|---|---|
| æè¦æµè§æ¬¡æ° | 357 | 125 | 13 |
| å ¨ææµè§æ¬¡æ° | 11 | 2 | 0 |
| PDFä¸è½½æ¬¡æ° | 15 | 7 | 0 |
Milk fermented by Lactobacillus casei CRL431 modifies cytokine profiles associated to different stages of breast cancer development in mice
äºBeneficial MicrobesSearch for other papers by V.E. Méndez Utz in
Current site
Google Scholar
PubMed
Cátedra de InmunologÃa. Facultad de BioquÃmica, QuÃmica y Farmacia. Universidad Nacional de Tucumán, San Miguel de Tucumán, Tucumán, Argentina.
Search for other papers by G. Perdigón in
Current site
Google Scholar
PubMed
Search for other papers by A. de Moreno de LeBlanc in
Current site
Google Scholar
PubMed
Breast cancer is one of the leading causes of death worldwide. It is recognised that immune system influences its promotion, progression, and metastasis, as well as their responsiveness to therapies. Previously, it was reported that milk fermented by Lactobacillus casei CRL431 decreased tumour growth and metastasis in a mouse breast cancer model, through the modulation of the host immune response. The aim of the present work was to analyse the systemic immune response induced by the administration of probiotic fermented milk (PFM) at different stages of cancer development, evaluating cytokines produced by splenocytes stimulated in vitro with 4T1 tumour cells, or its conditioned medium (CM). Groups of healthy mice and mice bearing 4T1 tumour or suffering metastasis after tumour surgery were studied. Results showed that at the early stages, PFM maintained pro-inflammatory response associated to the delay or the inhibition of tumour growth. PFM administration to mice bearing tumour maintained an important inflammatory response; however, in contrast to the milk group, this response was regulated to avoid exacerbation of inflammation. In the metastasis model, the benefits of PFM were associated to avoid the immunosuppression associated to high interleukin-10 levels. In conclusion, as cancer cells induce modifications of the immune response to favour their own growth at each stage of cancer development, PFM administration stimulated different profile of cytokines to respond to these modifications and fight against cancer cells.
| å ¨é¨æé´ | è¿å»ä¸å¹´ | è¿å»30天 | |
|---|---|---|---|
| æè¦æµè§æ¬¡æ° | 357 | 125 | 13 |
| å ¨ææµè§æ¬¡æ° | 11 | 2 | 0 |
| PDFä¸è½½æ¬¡æ° | 15 | 7 | 0 |
